RuiYi Raises $15M For Monoclonal Antibody Research

La Jolla-based RuiYi, a company developing therapeutic monoclonal antibodies, said today that it has raised $15M in a Series B financing. The funding came from 5AM Ventures, Versant Ventures, Apposite Capital, SR One, Merck Serono Ventures, and Aravis SA. The company said the funding will gotwards continued development of its lead compound. RuiYi has its executive headquarters in La Jolla, but is conducting research in China, via facilities in Pudong, Shanghai, China. More information »